JANX Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.

$14.13  +1.22 (9.45%)
As of 10/04/2022 15:59:46 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/11/2021
Outstanding shares:  41,663,029
Average volume:  61,694
Market cap:   $564,117,413
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BMFX8Y7
Valuation   (See tab for details)
PE ratio:   -12.28
PB ratio:   1.50
PS ratio:   176.01
Return on equity:   -12.30%
Net income %:   -1,366.55%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy